Education
About Us
Working with TipRanks
Follow Us
Standard Biotools Inc (LAB)
:LAB
Top Page
Standard BioTools
(NASDAQ:LAB)
39Underperform
Positive Factors
Operational Improvements
LAB management continues to make progress on underlying operations and is targeting improvements despite headwinds.
Technology Partnerships
ILMN announced a pilot proteomics program to analyze 50,000 U.K. Biobank samples based on Illumina's upcoming proteomics assay, Illumina Protein Prep, powered by LAB's SOMAmer technology.
Negative Factors
Leadership Changes
The CFO departure (personal reasons) is a negative surprise though management is steadfast key drivers (synergies, ILMN partnership) are unchanged.
Market Headwinds
The '25 revenue was guided to $165-175M, disappointing versus consensus due to market headwinds like capex budgets and NIH uncertainty.
Revenue Guidance
LAB posted disappointing initial 2025 revenue guidance of $165M-$175M vs. consensus of $186.9M.
Standard BioTools (LAB) vs. S&P 500 (SPY)
Market Cap
$405.52M
Dividend YieldN/A
Average Volume (3M)2.00M
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth64.03%
EPS Growth41.46%
CountryUS
Employees814
SectorHealthcare
Sector Strength77
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.55
Shares Outstanding378,986,360
10 Day Avg. Volume1,299,953
30 Day Avg. Volume2,004,669
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.63
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.50Price Target Upside133.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Standard BioTools Business Overview & Revenue Model
Company DescriptionStandard BioTools (formerly known as Fluidigm Corporation) operates in the life sciences sector, focusing on providing innovative tools and technologies for biological research and development. The company's core products include advanced analytical instruments, microfluidic systems, and consumables that facilitate high-throughput genomics, proteomics, and single-cell analysis. These products support various applications in research laboratories, pharmaceutical companies, and academic institutions, aiding in the exploration of complex biological systems and the advancement of precision medicine.
How the Company Makes MoneyStandard BioTools generates revenue primarily through the sale of its analytical instruments and consumables. The company offers a range of products that cater to different aspects of biological research, including genomics and proteomics. Revenue streams include direct sales to research institutions and laboratories, as well as partnerships and collaborations with pharmaceutical companies that utilize its technology for drug discovery and development. Additionally, the company may earn from service agreements, training, and customer support related to its products. Significant factors contributing to its earnings include the growing demand for advanced research tools in the life sciences sector and its ability to innovate and create technologies that address emerging research needs.
Standard BioTools Financial Statement Overview
Summary
Standard BioTools faces significant financial challenges with continuous net losses and declining revenue. Despite a stable balance sheet, poor cash flow generation and persistent operating losses pose substantial risks. Improving revenue growth is critical for future improvement.Income Statement
The company has experienced a decline in revenue over recent years, with Total Revenue decreasing from $138.1 million in 2020 to $106.3 million in 2023. Gross Profit Margin remains stable but negative Net Profit Margins indicate continuous losses. EBIT and EBITDA margins are negative, mirroring sustained operating losses. The revenue growth is negative, reflecting challenges in the company's ability to expand its market presence.35
Negative
Balance Sheet
The balance sheet shows a moderate level of stability with a strong equity base as Stockholders' Equity increased significantly by 2023. The Debt-to-Equity Ratio decreased, indicating lower financial leverage. The Equity Ratio has improved, suggesting a stronger asset base relative to equity. However, persistent losses impact overall financial health.42
Neutral
Cash Flow
The company's cash flow situation is concerning, with negative Free Cash Flow and Operating Cash Flow to Net Income ratios. Free Cash Flow has declined significantly, indicating poor cash generation capabilities. The Operating Cash Flow has been consistently negative, highlighting operational inefficiencies.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 174.43M | 106.34M | 97.95M | 130.58M | 138.14M | Gross Profit |
| 84.26M | 50.45M | 37.05M | 69.37M | 83.33M | EBIT |
| -175.24M | -76.60M | -116.20M | -67.46M | -51.04M | EBITDA |
| -118.14M | -54.46M | -173.57M | -43.77M | -34.60M | Net Income Common Stockholders |
| -138.88M | -74.66M | -190.10M | -59.24M | -53.02M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 292.87M | 114.89M | 165.78M | 28.45M | 68.52M | Total Assets |
| 612.34M | 323.07M | 390.31M | 275.21M | 324.76M | Total Debt |
| 33.00M | 98.21M | 102.66M | 111.65M | 95.38M | Net Debt |
| -133.73M | 46.51M | 21.35M | 83.20M | 26.86M | Total Liabilities |
| 140.62M | 159.87M | 471.78M | 180.62M | 185.71M | Stockholders Equity |
| 471.72M | 163.20M | -81.47M | 94.60M | 139.05M |
| Cash Flow | Free Cash Flow | |||
| -151.81M | -46.12M | -93.19M | -57.33M | -28.13M | Operating Cash Flow |
| -143.45M | -43.29M | -89.37M | -44.06M | -15.42M | Investing Cash Flow |
| 363.17M | 20.24M | -88.13M | -11.95M | 39.98M | Financing Cash Flow |
| -102.62M | -6.81M | 230.76M | 15.96M | 20.86M |
Standard BioTools Technical Analysis
Negative
1.07
Price Trends
1.26
Negative
1.55
Negative
1.74
Negative
Market Momentum
-0.05
Negative
40.58
Neutral
23.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.26, and below the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.58 is Neutral, neither overbought nor oversold. The STOCH value of 23.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.
Standard BioTools Risk Analysis
Standard BioTools disclosed 53 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Standard BioTools Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $165.21B | 26.48 | 13.15% | 0.36% | 0.05% | 6.87% | |
68 Neutral | $29.37B | 23.67 | 20.61% | 0.93% | -3.00% | 3.67% | |
65 Neutral | $130.05B | 34.37 | 7.57% | 0.62% | -13.50% | -17.25% | |
49 Neutral | $6.33B | ― | -24.09% | ― | -3.92% | -202.80% | |
49 Neutral | $11.75B | ― | -30.11% | ― | -2.93% | -4.69% | |
48 Neutral | $6.36B | 1.14 | -49.00% | 2.63% | 17.14% | 1.39% | |
39 Underperform | $405.52M | ― | -43.75% | ― | 64.03% | 41.46% |
* Healthcare Sector Average
Performance Comparison
LAB
Standard BioTools
1.10
-1.78
-61.81%
A
Agilent
103.00
-40.39
-28.17%
BIO
Bio-Rad Laboratories
225.60
-100.72
-30.87%
DHR
Danaher
181.77
-61.32
-25.23%
ILMN
Illumina
73.45
-53.01
-41.92%
TMO
Thermo Fisher
437.91
-139.21
-24.12%
Standard BioTools Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: -8.55% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Neutral
Despite the successful realization of cost synergies and a strong balance sheet, the company faced significant revenue declines and market challenges, including reduced instrument sales and potential impacts from NIH funding and tariffs. The growth in consumables and strategic initiatives in proteomics provide optimism, but the current market and economic environment pose challenges.Highlights
Cost Synergies and Operational Improvements
Operationalized $80 million in cost synergies a year ahead of plan, with an additional $10 million in cost reductions. Achieved a 22% year-over-year reduction in non-GAAP operating expenses and a 33% improvement in adjusted EBITDA.
Strong Balance Sheet
Nearly $300 million in cash with substantially no debt, providing flexibility to execute strategic plans and potential acquisitions.
Consumables Growth
Consumables revenue grew 10% in the fourth quarter and 18% for the full year 2024, driven by SomaScan authorized sites and the Illumina early access program.
Proteomics and Illumina Partnership
SomaScan platform is positioned as a leader in plasma proteomics, with a strategic partnership with Illumina, unlocking large-scale protein analysis opportunities. Expecting a significant market opportunity, estimated at $1 billion.
Lowlights
Revenue Decline
Fourth quarter and full year 2024 revenue declined 9% year-over-year, impacted by softness in instruments and services.
Instrument Sales Decline
Instrument sales were down 25% in Q4 and 27% for the year, primarily due to capital spending constraints.
Market and Economic Challenges
Anticipated reduction in NIH spending and academic revenue, potential impacts from tariffs, and cautious spending in biopharma and academia.
Service Revenue Decline
Lab Services sales were down 18% in Q4 and 21% for the year, affected by high customer concentration and variability in demand from large pharma accounts.
Company Guidance
During the fourth quarter and full year 2024 financial results call, Standard BioTools provided a comprehensive overview of their performance and outlined guidance for 2025. The company reported $46.7 million in revenue for the fourth quarter and $175.1 million for the full year, both reflecting a 9% year-over-year decline. Despite the revenue drop, the company achieved a 33% improvement in adjusted EBITDA compared to 2023, driven by $80 million in cost synergies operationalized through the merger with SomaLogic. Looking forward, Standard BioTools anticipates 2025 organic revenue between $165 million and $175 million, an approximate 3% decline at the midpoint, factoring in anticipated headwinds such as a mid-teens percentage decline in Americas academic revenue due to potential NIH funding cuts. The company maintains a strong balance sheet with nearly $300 million in cash, positioning it to execute strategic plans and fund potential acquisitions. They remain on track to reach adjusted EBITDA breakeven in 2026, even as they navigate macroeconomic challenges and evolving market conditions.Standard BioTools Corporate Events
Business Operations and StrategyFinancial Disclosures
Standard BioTools Reports 2024 Financial Results and Strategic Outlook
Neutral
Feb 26, 2025
Standard BioTools reported its financial results for the fourth quarter and full year 2024, highlighting a pro forma combined revenue of $175.1 million, a 9% decrease year-over-year. The company achieved significant operational cost reductions totaling $90 million in synergies over 12 months, and improved its adjusted EBITDA by 33% year-over-year. Despite a net loss of $34.1 million in Q4 2024, the company has a strong balance sheet with $295 million in cash and no material debt, positioning it for future growth and strategic acquisitions. Looking forward, Standard BioTools aims to focus on higher-margin offerings and capitalize on a billion-dollar opportunity in the proteomics market with its upcoming NGS-based solution in partnership with Illumina.
Business Operations and StrategyFinancial Disclosures
Standard BioTools Reports 2024 Revenue Achievements and Plans
Positive
Jan 13, 2025
Standard BioTools announced preliminary, unaudited revenue results for the fourth quarter and full year 2024, reporting approximately $46.5 million for the quarter and $174 million for the year. Despite industry-wide challenges, the company reached the upper end of its revised forecast and has been implementing the Standard BioTools Business Systems to reduce operating expenses. The company plans to further enhance efficiencies and shift towards high-margin markets in 2025, aiming to deliver long-term value to shareholders and customers.
Executive/Board Changes
Standard BioTools Announces CCO Jeremy Davis’s Departure
Neutral
Jan 10, 2025
Standard BioTools Inc. announced that their Chief Commercial Officer, Jeremy Davis, will step down from his position effective February 1, 2025. The company will enter into a severance agreement with Davis, which includes a continuation of salary payments totaling $441,000 over a year, a bonus for the 2024 fiscal year, a pro-rated target bonus, payment of COBRA premiums, and full vesting of equity awards, indicating a structured transition plan for the leadership change.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.